[1]高飞, 葛志敏, 郭中豪, 等. 甲状旁腺激素对大鼠骨髓间充质干细胞成脂分化的影响[J]. 中华风湿病学杂志, 2015, 19(4):249-253. [2]刘长永. 甲状旁腺激素和阿仑膦酸钠对男性骨质疏松患者骨密度的影响[J]. 中国老年学杂志, 2015, 35(7):1972-1973. [3]Amizuka N, Hasegawa T, Oda K, et al. Histology of epiphyseal cartilage calcification and endochondral ossification[J]. Front Biosci (Elite Ed), 2012, 4:2085-2100. [4]李春雨, 杨德鸿, 孟越, 等. 甲状旁腺激素(1-34)对小鼠肺癌骨转移瘤生长的影响[J]. 南方医科大学学报, 2014, 34(9):1295-1300. [5]吴素珍, 李加林. 甲状旁腺激素相关蛋白研究进展[J]. 中国生化药物杂志, 2015, 35(7):157-160,164. [6]熊红珍, 徐会勇, 李松, 等. 甲状旁腺激素相关蛋白mRNA在髁突软骨与生长板软骨发育早期的表达变化[J]. 广东牙病防治, 2012, 20(8):409-412. [7]薛妍, 张惠利, 车彦海, 等. 甲状旁腺激素(1-34)联合珊瑚转化型羟基磷灰石促进种植体周围骨缺损再生修复的实验研究[J]. 中华口腔医学杂志, 2015, 50(2):99-102. [8]张梦媛, 任安. 甲状腺功能亢进患者硬骨素与骨代谢的关系[J]. 天津医药, 2014, 42(9):908-911. [9]吕芳, 李梅. 甲状旁腺激素制剂治疗代谢性骨病[J]. 国际内分泌代谢杂志, 2014, 34(3):180-183. [10]刘冰, 卢蕾阳, 高飞, 等. 胰岛素样生长因子-1对甲状旁腺激素介导成骨细胞增殖及成骨活性的影响[J]. 中国骨质疏松杂志, 2014, 20(11):1298-1301. [11] Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing[J]. Arch Orthop Trauma Surg, 2014, 134(2):291-297. [12] Liu J, Lv F, Sun W, et al. The abnormal phenotypes of cartilage and bone in calcium-sensing receptor deficient mice are dependent on the actions of calcium, phosphorus, and PTH[J]. PLoS Genet, 2011, 7(9):e1002294. [13] Sampson ER, Hilton MJ, Tian Y, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis[J]. Sci Transl Med, 2011, 3(101):101ra93. [14] Gebhard S, Hattori T, Bauer E, et al. Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter[J]. Matrix Biol, 2008, 27(8):693-699. [15] Saito T, Fukai A, Mabuchi A, et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development[J]. Nat Med, 2010, 16(6): 678-686. |